Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma

Literature DB >> 34092058

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.

Niels Weinhold¹, Hans J Salwender², David A Cairns³, Marc S Raab⁴, George Waldron⁵, Igor W Blau⁶, Uta Bertsch⁴, Thomas Hielscher⁷, Gareth J Morgan⁸, Anna Jauch⁹, Faith E Davies⁸, Mathias Hänel¹⁰, Gordon Cook¹¹, Christoph Scheid¹², Richard Houlston⁵, Hartmut Goldschmidt¹³, Graham Jackson¹⁴, Martin F Kaiser¹⁵.

Abstract

Not available.

Entities: Disease Species

Year: 2021 PMID： 34092058 DOI： 10.3324/haematol.2021.278888

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

7 in total

1. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.

Authors: Yu-Tong Wang; Li Bao; Bin Chu; Xiao-Huan Chen; Min-Qiu Lu; Lei Shi; Shan Gao; Li-Juan Fang; Qiu-Qing Xiang; Yue-Hua Ding
Journal: J Clin Lab Anal Date: 2022-03-30 Impact factor: 3.124

2. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.

Authors: Adrian Mosquera Orgueira; Marta Sonia González Pérez; Jose Diaz Arias; Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Joaquin Martinez Lopez; Luis Palomera; Miguel Granell; Maria Jesus Blanchard; Javier de la Rubia; Ana López de la Guia; Rafael Rios; Anna Sureda; Miguel Teodoro Hernandez; Enrique Bengoechea; María José Calasanz; Norma Gutierrez; Maria Luis Martin; Joan Blade; Juan-Jose Lahuerta; Jesús San Miguel; Maria Victoria Mateos
Journal: Blood Cancer J Date: 2022-04-25 Impact factor: 9.812

Review 3. Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.

Authors: Francesca Bonello; Lorenzo Cani; Mattia D'Agostino
Journal: Front Oncol Date: 2022-03-09 Impact factor: 6.244

4. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.

Authors: Hoi Ki Karen Tang; Chi Yeung Fung; Gareth J Morgan; Shaji Kumar; Lisa Siu; Ho Wan Alvin Ip; Sze Fai Yip; Ka Ngai Harry Lau; Chi Kuen Lau; Harold Lee; Kwan Hung Leung; Bonnie Kho; Howard Wong; Cheong Ngai; Yu Yan Hwang; Joycelyn Sim; Yok Lam Kwong; Chor Sang Chim
Journal: Ther Adv Hematol Date: 2022-04-18

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.

1. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.

2. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.

Review 3. Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.

4. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.

5. Exploiting gene dependency to inform drug development for multiple myeloma.

6. The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma.

Review 7. Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.